Circulating adipokines data associated with insulin secretagogue use in breast cancer patients

Data in Brief

卷:10

Jeffrey P. Hammel¹  Dan P. Gaile²  Zachary A.P. Wintrob³  Alice C. Ceacareanu³  George K. Nimako³  Zahra S. Fayazi³  Alan Forrest⁴ 

[1] Cleveland Clinic, Department of Biostatistics and Epidemiology, 9500 Euclid Ave., Cleveland, OH 44195, United States;

[2] State University of New York at Buffalo, Department of Biostatistics, 718 Kimball Tower, Buffalo, NY 14214, United States;

[3] State University of New York at Buffalo, Department of Pharmacy Practice, NYS Center of Excellence in Bioinformatics and Life Sciences, 701 Ellicott Street, Buffalo, NY 14203, United States;

[4] The UNC Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, Campus Box 7569, Chapel Hill, NC 27599, United States;

关键词: Adipokine;    Insulin;    Secretagogue;    Breast cancer;    Diabetes;    Cancer outcomes;    Cancer prognosis;   

DOI  :  10.1016/j.dib.2016.11.060

来源: DOAJ

【 摘 要 】

Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in “Insulin use, adipokine profiles and breast cancer prognosis” (Wintrob et al., in press) [1].

【 授权许可】

Unknown